CommercialCoverageMedium impact
06.02.53, Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Independence Blue Cross·Urology, Oncology, Internal Medicine +1 more·Medical Policy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
This policy covers protein biomarkers for prostate cancer diagnosis and risk assessment. The policy has been reissued with an effective date of March 4, 2026, indicating updated coverage criteria or billing guidelines for prostate cancer biomarker testing.
Action Required
By March 4, 2026: Review updated policy 06.02.53 for protein biomarkers in prostate cancer diagnosis and risk assessment. Billing team should verify current coverage criteria and documentation requirements for prostate cancer biomarker tests. Update billing protocols and prior authorization procedures as specified in the full policy document.